An Act to amend and reenact § 54.1-3446 of the Code of Virginia, relating to Drug Control Act; Schedule I; penalties.
HB558 amends Virginia’s Drug Control Act by revising the state’s Schedule I controlled substances list in § 54.1-3446. The bill adds a long list of specific synthetic opioids and related compounds, including several fentanyl analogs, nitazenes, and other emerging designer drugs such as brorphine, AP-237, etonitazene variants, metonitazene, methoxyacetyl fentanyl, U-47700, AH-7921, and tianeptine. It also retains the statute’s general structure covering opiates and their isomers, esters, ethers, and salts when chemically possible.
As a Schedule I update, the bill places the newly listed substances under Virginia’s most restrictive controlled-substances category, making their manufacture, distribution, possession, and other handling subject to the state’s criminal and regulatory penalties applicable to Schedule I drugs. The practical effect is to align Virginia law with the evolving illicit drug market by explicitly naming compounds that have emerged as abuse or overdose risks, reducing ambiguity for law enforcement, prosecutors, and regulated entities.
The available legislative record shows no committee transcript excerpts and no recorded votes in the provided materials, so there is little direct evidence of debate or opposition in the context supplied. The bill was enacted as Chapter 171 and approved on April 6, 2026, which suggests it moved through the process without notable recorded controversy in the materials provided.
The main point of policy significance is the state’s effort to keep pace with rapidly changing synthetic opioid chemistry. Because the bill targets a broad set of newly identified substances, it likely reflects concern about overdose prevention, drug trafficking, and closing loopholes that can arise when illicit chemists alter molecular structures to evade existing schedules. Any contention would most likely center on the breadth of Schedule I classification and the criminalization of substances that may have limited medical or research use, but no such objections are documented in the supplied record.
HB558 amends § 54.1-3446 of the Code of Virginia, expanding and updating the Schedule I controlled substances list under the Drug Control Act. The change directly affects criminal enforcement, prosecution, and regulatory treatment of the newly named substances by making them subject to Virginia’s Schedule I restrictions and penalties. It primarily impacts individuals and entities involved in the manufacture, distribution, possession, or trafficking of synthetic opioids and related designer drugs, as well as law enforcement and forensic laboratories that must identify and enforce against these compounds.
The overall sentiment reflected in the provided record appears neutral to supportive, with the bill enacted into law and no committee testimony or vote history indicating organized opposition. The absence of recorded debate suggests the measure was treated as a technical but important public-safety update to the controlled substances schedule. The enactment as Chapter 171 indicates legislative acceptance of the need to keep the Schedule I list current with emerging synthetic drugs.
No specific contention is documented in the supplied transcripts or vote history. Based on the bill’s subject matter, any likely concerns would involve the scope of Schedule I scheduling, the inclusion of compounds such as tianeptine or other substances that may have legitimate uses in some contexts, and the broader policy tradeoff between public safety enforcement and overbroad criminalization. However, the provided materials do not show any named opponents, amendments, or recorded disputes.